

32. (New) A mammalian non-plasmocyte cell genetically modified with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence coding for a native, unmodified antibody molecule:
- (a) wherein the nucleotide sequence coding for the antibody molecule is operably linked to a promoter for expressing the nucleotide sequence encoding the antibody molecule in the mammalian non-plasmocyte cell, and
  - (b) wherein the nucleic acid comprises a sequence for termination of the transcription, situated downstream from the sequence coding for the antibody molecule and a sequence permitting the secretion of the antibody molecule from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal, and
- wherein the genetically-modified mammalian non-plasmocyte cell, when administered to a mammal, produces the antibody molecule *in vivo* and is suitable for remaining in the mammal for several months.
33. (New) The cell of claim 32, wherein the nucleic acid comprises a polynucleotide coding for an antibody polypeptide,
- (i) wherein the coding polynucleotide is operably linked to a promoter for expressing the polynucleotide encoding the antibody polypeptide in the mammalian non-plasmocyte cell *in vivo*; and
  - (ii) wherein the coding polynucleotide is operably linked to a polynucleotide element required for the secretion of the antibody polypeptide from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal.
34. (New) The cell of claim 32, wherein the native, unmodified antibody molecule is selected from the group consisting of: a single antibody heavy chain, a single antibody light chain, and an antibody molecule comprising a heavy chain and a light chain.

35. (New) The cell of claim 32, wherein the nucleic acid is inserted in a vector.
36. (New) The cell of claim 32, wherein the vector is a viral vector.
37. (New) The cell of claim 32, wherein the cell is selected from the group consisting of: keratinocyte, hepatocyte, fibroblast, myoblast, endothelial cell, and hematopoietic cell.
38. (New) The cell of claim 32, wherein the antibody is directed against a tumor cell antigen.
39. (New) The cell of claim 32, wherein the antibody is directed against a virus.
40. (New) A method of making a mammalian non-plasmocyte cell comprising a nucleic acid containing a polynucleotide coding for a native, unmodified antibody polypeptide, comprising the step of transferring, upon transfection, at least one nucleic acid comprising a polynucleotide coding for said native, unmodified antibody polypeptide,
- (a) wherein the coding polynucleotide is operably linked to a promoter for expressing the polynucleotide encoding the antibody polypeptide in the mammalian non-plasmocyte cell; and
  - (b) wherein the coding polynucleotide is operably linked to a polynucleotide element required for the secretion of the antibody polypeptide from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell.
41. (New) The method of claim 40, wherein the native, unmodified antibody molecule is selected from the group consisting of: a single antibody heavy chain, a single antibody light chain, and an antibody molecule comprising a heavy chain and a light chain.

42. (New) A method for delivering an antibody to the blood system of a host mammal, comprising: implanting a cell into a mammal,
- (a) wherein the implanted cell is a mammalian non-plasmocyte cell genetically modified with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence coding for a native, unmodified antibody molecule;
  - (b) wherein the nucleotide sequence coding for the native, unmodified antibody molecule is operably linked to a promoter for expressing said nucleotide sequence coding the antibody molecule in the mammalian non-plasmocyte cell; and
  - (c) wherein the nucleic acid comprises a sequence for termination of the transcription, situated downstream from the sequence coding for an antibody molecule and a sequence permitting the secretion of said antibody molecule from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal.
-